Pfizer Proposes Criteria To Allow Free Phytosterol CHD Reduction Claim
This article was originally published in The Tan Sheet
FDA should allow CHD reduction claims for nonesterified phytosterol supplements to that disperse efficiently from tablet form and help block cholesterol uptake, Pfizer argues in comments to the agency.
You may also be interested in...
FDA will give firms a year to relabel or reformulate dietary supplements with nonesterified phytosterols to comply with a proposed rule that overhauls a health claim linking phytosterols to a reduced risk of coronary heart disease.
Dietary supplement industry stakeholders "urgently" ask FDA to continue allowing coronary heart disease reduction health claims for supplements with nonesterified phytosterols, or risk "irreparable injury" to some firms.
FDA significantly overhauls a health claim linking phytosterols to a reduced risk of coronary heart disease, expanding the type of enriched conventional foods and forms of dietary supplements that can make the claim.